Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma.
Raje N et al. Clin Cancer Res. 2016 Jun 10. pii: clincanres.0201.2016. [Epub ahead of print].

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin AM et al. J Clin Oncol. 2016 Jun 6. pii: JCO659789. [Epub ahead of print].

Venetoclax: First Global Approval.
Deeks ED et al. Drugs. 2016 Jun;76(9):979-87. doi: 10.1007/s40265-016-0596-x

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, inMyeloma.
Moreau P et al. Drugs. 2016 Jun;76(9):989-990.

Emerging antibodies for the treatment of multiple myeloma.
Zagouri F et al. Expert Opin Emerg Drugs. 2016 Jun;21(2):225-37. doi: 10.1080/14728214.2016.1186644.